Journal article · 2025 · Open access

Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer

Laurie Batchelder, Laure Guéroult-Accolas, Eirini Anastasaki, K. Dunton, Diana Lüftner, Corinna Oswald, James Ryan, Doris C. Schmitt, Veronika Steinerova, Della Varghese, Sukhvinder Johal

MDM Policy & Practice, 10(2), 23814683251372622 · Published 1 July 2025 · DOI 10.1177/23814683251372622

Open full textCite this paper

In brief

“Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer” is a 2025 journal article by Laurie Batchelder and 10 co-authors, published in MDM Policy & Practice. OpenAlex counts 1 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at MDM Policy & Practice.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.51
References
40
Authors
11

Abstract

Purpose. Health technology assessment (HTA) focuses on overall survival (OS) as the key clinical endpoint when making oncology treatment decisions. However, capturing robust OS estimates in early-stage breast cancer (eBC) is challenging, and patients may value other endpoints. This study assessed patient preferences for treatment attributes and endpoints in neoadjuvant therapy where mature and nonconfounded OS is rarely available. Patients and Methods. An online discrete choice experiment (DCE) was developed with health care professionals and patient advisory groups and conducted in Germany, France, Italy, and Spain with patients with HER2+ eBC. Patients were presented with 15 tasks and in each asked to choose between 2 hypothetical treatment options or to opt out in the neoadjuvant setting. Treatment attributes included OS at 5-years, disease-free survival (DFS) at 5-years, pathological complete response (pCR), impact of side effects on quality of life (QoL), and ability to receive breast-conserving surgery (BCS). Data were analyzed using multinomial logit and random parameters logit models. Results. Three hundred thirty-four patients with HER2+ eBC responded. The most valued attribute was achieving pCR (no invasive cancer in the breast and lymph nodes in all patients after treatment), followed by 5-y DFS in 95% of patients. OS ranked third in importance. The ability to undergo BCS and the impact of side effects on QoL were less important. Preferences varied by hormone receptor status, time since diagnosis, cancer stage, and age. Conclusion. Our findings are in-line with regulatory reviews, which accept pCR, DFS, and OS as clinically valid endpoints. When recommending reimbursements for treatments, HTA bodies and payers should consider patient preferences for treatment attributes and endpoints in their decision making when valuing new cancer treatments. Highlights Traditional cancer treatment assessments focus on overall survival (OS), but in early-stage breast (eBC) cancer, patients may prioritize other treatment outcomes, since robust OS data may be unavailable. A discrete choice experiment was conducted with 334 patients with HER2+ eBC in the neoadjuvant setting in Germany, France, Italy, and Spain. Patients considered achieving pathological complete response (no invasive cancer in the breast and lymph nodes in all patients after treatment) to be the most important attribute when making a treatment decision, followed by disease free-survival (DFS) and OS; the ability to undergo breast-conserving surgery and the impact of side effects on quality of life were less important. These insights highlight the need for health authorities and reimbursement bodies to consider patient-valued outcomes beyond OS in eBC treatment evaluations.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Batchelder, L., Guéroult-Accolas, L., Anastasaki, E., Dunton, K., Lüftner, D., Oswald, C., Ryan, J., Schmitt, D. C., Steinerova, V., Varghese, D., & Johal, S. (2025). Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer. MDM Policy & Practice, 10(2), 23814683251372622. https://doi.org/10.1177/23814683251372622

MLA 9

Batchelder, Laurie, et al. “Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer.” MDM Policy & Practice, vol. 10, no. 2, 2025, p. 23814683251372622. https://doi.org/10.1177/23814683251372622.

Chicago

Batchelder, Laurie, Laure Guéroult-Accolas, Eirini Anastasaki, K. Dunton, Diana Lüftner, Corinna Oswald, James Ryan, et al. 2025. “Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer.” MDM Policy & Practice 10 (2): 23814683251372622. https://doi.org/10.1177/23814683251372622.

Harvard

Batchelder, L. et al. (2025) ‘Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer’, MDM Policy & Practice, 10(2), p. 23814683251372622. doi:10.1177/23814683251372622.

IEEE

L. Batchelder et al., “Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer,” MDM Policy & Practice, vol. 10, no. 2, p. 23814683251372622, 2025, doi: 10.1177/23814683251372622.

BibTeX

@article{batchelder2025patient,
  title     = {{Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer}},
  author    = {Batchelder, Laurie and Guéroult-Accolas, Laure and Anastasaki, Eirini and Dunton, K. and Lüftner, Diana and Oswald, Corinna and Ryan, James and Schmitt, Doris C. and Steinerova, Veronika and Varghese, Della and Johal, Sukhvinder},
  journal   = {MDM Policy \& Practice},
  year      = {2025},
  volume    = {10},
  number    = {2},
  pages     = {23814683251372622},
  doi       = {10.1177/23814683251372622},
  url       = {https://doi.org/10.1177/23814683251372622}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient preferences
  • HER2-positive breast cancer
  • early breast cancer
  • neoadjuvant therapy
  • health technology assessment
  • pathological complete response
  • disease-free survival
  • overall survival

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Batchelder, L., Guéroult-Accolas, L., Anastasaki, E., Dunton, K., Lüftner, D., Oswald, C., Ryan, J., Schmitt, D. C., Steinerova, V., Varghese, D., & Johal, S. (2025). Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer. MDM Policy & Practice, 10(2), 23814683251372622. https://doi.org/10.1177/23814683251372622

How many times has this paper been cited?

1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at MDM Policy & Practice: sign in and open the full text from this page.

Who wrote this paper?

Laurie Batchelder, Laure Guéroult-Accolas, Eirini Anastasaki, K. Dunton, Diana Lüftner, Corinna Oswald, James Ryan, Doris C. Schmitt, Veronika Steinerova, Della Varghese, Sukhvinder Johal.

What is the DOI of this paper?

10.1177/23814683251372622, permanently at https://doi.org/10.1177/23814683251372622. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.